Movement Alert｜Edwards Lifesciences Rises 3.53% in Regular Trading, CMS TAVR National Coverage Determination Memo Continues to Serve as Positive Catalyst

Market Focus06-24 22:01

On June 24, Edwards Lifesciences rose 3.53% in regular trading, trading at $90.2/share, with turnover of $54.138 million. The gain was driven by the continued positive impact of a CMS-issued TAVR National Coverage Determination memo.

RBC Capital Markets previously identified the memo as a significant catalyst for Edwards Lifesciences. According to RBC's physician survey, the coverage scope change could drive approximately 5% growth in national TAVR procedure volumes. Notably, the transition to a single-operator model is expected to yield the most significant improvement in surgical efficiency, accompanied by an expansion of eligible procedure sites. These factors collectively enhance Edwards' revenue outlook in its core transcatheter heart valve replacement business.

Within the Health Care Equipment sector, Stryker rose 2.4%, Abbott Laboratories rose 2.11%, and Intuitive Surgical rose 1.09%, reflecting broad sector strength.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1127008856?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127008856","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Edwards Lifesciences Rises 3.53% in Regular Trading, CMS TAVR National Coverage Determination Memo Continues to Serve as Positive Catalyst","media":"Market Focus","content":"<p><p>On June 24, Edwards Lifesciences rose 3.53% in regular trading, trading at $90.2/share, with turnover of $54.138 million. The gain was driven by the continued positive impact of a CMS-issued TAVR National Coverage Determination memo.</p><p>RBC Capital Markets previously identified the memo as a significant catalyst for Edwards Lifesciences. According to RBC's physician survey, the coverage scope change could drive approximately 5% growth in national TAVR procedure volumes. Notably, the transition to a single-operator model is expected to yield the most significant improvement in surgical efficiency, accompanied by an expansion of eligible procedure sites. These factors collectively enhance Edwards' revenue outlook in its core transcatheter heart valve replacement business.</p><p>Within the Health Care Equipment sector, Stryker rose 2.4%, Abbott Laboratories rose 2.11%, and Intuitive Surgical rose 1.09%, reflecting broad sector strength.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Edwards Lifesciences Rises 3.53% in Regular Trading, CMS TAVR National Coverage Determination Memo Continues to Serve as Positive Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Edwards Lifesciences Rises 3.53% in Regular Trading, CMS TAVR National Coverage Determination Memo Continues to Serve as Positive Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-24 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 24, Edwards Lifesciences rose 3.53% in regular trading, trading at $90.2/share, with turnover of $54.138 million. The gain was driven by the continued positive impact of a CMS-issued TAVR National Coverage Determination memo.</p><p>RBC Capital Markets previously identified the memo as a significant catalyst for Edwards Lifesciences. According to RBC's physician survey, the coverage scope change could drive approximately 5% growth in national TAVR procedure volumes. Notably, the transition to a single-operator model is expected to yield the most significant improvement in surgical efficiency, accompanied by an expansion of eligible procedure sites. These factors collectively enhance Edwards' revenue outlook in its core transcatheter heart valve replacement business.</p><p>Within the Health Care Equipment sector, Stryker rose 2.4%, Abbott Laboratories rose 2.11%, and Intuitive Surgical rose 1.09%, reflecting broad sector strength.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EW","symbol_name":"爱德华兹","start_time":0,"source_url":"","article_id":"1127008856","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127008856","pubTimestamp":1782309710,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 24, Edwards Lifesciences rose 3.53% in regular trading, trading at $90.2/share, with turnover of $54.138 million. The gain was driven by the continued positive impact of a CMS-issued TAVR...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EW":"爱德华兹"},"translate_title":"动向提示|Edwards Lifesciences常规交易上涨3.53%，CMS TAVR全国覆盖范围确定备忘录继续成为积极催化剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EW":1},"content_text":"On June 24, Edwards Lifesciences rose 3.53% in regular trading, trading at $90.2/share, with turnover of $54.138 million. The gain was driven by the continued positive impact of a CMS-issued TAVR National Coverage Determination memo.RBC Capital Markets previously identified the memo as a significant catalyst for Edwards Lifesciences. According to RBC's physician survey, the coverage scope change could drive approximately 5% growth in national TAVR procedure volumes. Notably, the transition to a single-operator model is expected to yield the most significant improvement in surgical efficiency, accompanied by an expansion of eligible procedure sites. These factors collectively enhance Edwards' revenue outlook in its core transcatheter heart valve replacement business.Within the Health Care Equipment sector, Stryker rose 2.4%, Abbott Laboratories rose 2.11%, and Intuitive Surgical rose 1.09%, reflecting broad sector strength.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1127008856","isCrawlerRequest":true}